Evidence map›Paper›PMID 27352635›Full record

ArticleThe Journal of urology2016

Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Michael S Leapman, Stephen J Freedland, William J Aronson, Christopher J Kane, Martha K Terris, Kelly Walker, Christopher L Amling, Peter R Carroll, Matthew R Cooperberg

Abstract readComparative Study
In one paragraph

Article in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Michael S LeapmanDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California. Electronic address: michael.leapman@yale.edu.
Stephen J FreedlandDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, California.
William J AronsonDepartment of Urology, University of California-Los Angeles Medical Center, Los Angeles, California.
Christopher J KaneDepartment of Urology, University of California-San Diego Health System, San Diego, California.
Martha K TerrisDepartment of Urology, Georgia Regents Health System, Augusta, Georgia.
Kelly WalkerDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California.
Christopher L AmlingDepartment of Urology, Oregon Health and Science University, Portland, Oregon.
Peter R CarrollDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California.
Matthew R CooperbergDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
IGF-I: A Nutrition-Regulated Target in Prostate CancerR01CA100938 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COHEN, PINCHAS · 2003 to 2007
$1.7M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA100938
6 · The paper itself

Abstract

purposeRacial disparities in the incidence and risk profile of prostate cancer at diagnosis among African-American men are well reported. However, it remains unclear whether African-American race is independently associated with adverse outcomes in men with clinical low risk disease. MATERIALS AND

methodsWe retrospectively analyzed the records of 895 men in the SEARCH (Shared Equal Access Regional Cancer Hospital) database in whom clinical low risk prostate cancer was treated with radical prostatectomy. Associations of African-American and Caucasian race with pathological biochemical recurrence outcomes were examined using chi-square, logistic regression, log rank and Cox proportional hazards analyses.

resultsWe identified 355 African-American and 540 Caucasian men with low risk tumors in the SEARCH cohort who were followed a median of 6.3 years. Following adjustment for relevant covariates African-American race was not significantly associated with pathological upgrading (OR 1.33, p = 0.12), major upgrading (OR 0.58, p = 0.10), up-staging (OR 1.09, p = 0.73) or positive surgical margins (OR 1.04, p = 0.81). Five-year recurrence-free survival rates were 73.4% in African-American men and 78.4% in Caucasian men (log rank p = 0.18). In a Cox proportional hazards analysis model African-American race was not significantly associated with biochemical recurrence (HR 1.11, p = 0.52).

conclusionsIn a cohort of patients at clinical low risk who were treated with prostatectomy in an equal access health system with a high representation of African-American men we observed no significant differences in the rates of pathological upgrading, up-staging or biochemical recurrence. These data support continued use of active surveillance in African-American men. Upgrading and up-staging remain concerning possibilities for all men regardless of race.

Indexed as

Black or African AmericanWhite PeopleDatabases, FactualHumansMaleMiddle AgedProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk AssessmentUnited StatesWatchful WaitingProstate-Specific AntigenAfrican Americansneoplasm gradingneoplasm stagingprostatic neoplasmswatchful waiting

Identifiers

PMID27352635
PMCPMC5542578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.